Price
$48.20
Increased by +2.82%
Dollar volume (20D)
79.82 M
ADR%
5.55
Earnings report date
May 5, 2025
Shares float
49.27 M
Shares short
5.13 M [10.41%]
Shares outstanding
61.38 M
Market cap
2.88 B
Beta
2.33
Price/earnings
11.08
20D range
37.92 60.60
50D range
33.70 60.60
200D range
30.67 60.60

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.

It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage.

Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Feb 25, 25 1.98
Increased by +350.00%
0.25
Increased by +692.00%
Nov 4, 24 -0.54
Increased by +6.90%
-0.60
Increased by +10.00%
Aug 6, 24 -0.50
Increased by +26.47%
-0.60
Increased by +16.67%
May 7, 24 3.26
Increased by +586.57%
1.19
Increased by +173.95%
Feb 27, 24 0.44
Increased by +163.77%
-0.03
Increased by +1.57 K%
Nov 2, 23 -0.58
Increased by +9.38%
-0.69
Increased by +15.94%
Aug 3, 23 -0.68
Increased by +19.05%
-0.65
Decreased by -4.62%
May 4, 23 -0.67
Decreased by -55.81%
-0.73
Increased by +8.22%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 170.64 M
Increased by +184.40%
131.67 M
Increased by +381.70%
Increased by +77.17%
Increased by +69.38%
Sep 30, 24 4.67 M
Increased by +N/A%
-33.21 M
Increased by +2.62%
Decreased by -710.37%
Decreased by N/A%
Jun 30, 24 4.17 M
Increased by +N/A%
-30.62 M
Increased by +20.40%
Decreased by -734.73%
Decreased by N/A%
Mar 31, 24 254.95 M
Increased by +N/A%
207.34 M
Increased by +759.71%
Increased by +81.32%
Decreased by N/A%
Dec 31, 23 60.00 M
Increased by +N/A%
27.34 M
Increased by +187.37%
Increased by +45.56%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-34.10 M
Decreased by -13.08%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by -100.00%
-38.46 M
Increased by +5.34%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by -100.00%
-31.43 M
Decreased by -51.47%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY